No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BIIB240712C232500
- 3.90
- +2.10+116.67%
15min DelayClose Jul 11 16:00 ET
5.90High1.30Low
2.50Open1.80Pre Close15 Volume29 Open Interest232.50Strike Price5.68KTurnover38.47%IV-0.17%PremiumJul 12, 2024Expiry Date4.30Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8643Delta0.0545Gamma51.48Leverage Ratio-0.6449Theta0.0039Rho44.49Eff Leverage0.0226Vega
Intraday
- 5D
- Daily
News
Express News | Biogen Inc : Piper Sandler Cuts Target Price to $313 From $335
Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $313
Piper Sandler analyst Christopher Raymond maintains $Biogen(BIIB.US)$ with a buy rating, and adjusts the target price from $335 to $313.According to TipRanks data, the analyst has a success rate of 51
Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating
Biogen (BIIB) has an average rating of outperform and price targets ranging from $200 to $350, according to analysts polled by Capital IQ.Price: 237.22, Change: +0.42, Percent Change: +0.18
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Morgan Stanley Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $311
Morgan Stanley analyst Terence Flynn maintains $Biogen(BIIB.US)$ with a buy rating, and adjusts the target price from $331 to $311.According to TipRanks data, the analyst has a success rate of 64.8%
Morgan Stanley Adjusts Price Target on Biogen to $311 From $331
Biogen (BIIB) has an average rating of outperform and price targets ranging from $200 to $350, according to analysts by Capital IQ.Price: 231.00, Change: -1.75, Percent Change: -0.75
Comments
Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
3
$Biogen(BIIB.US$ perhaps some puts on this 0.0
Keep an eye on these M&As: 👀
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Harmony Biosciences(HRMY.US$ acquired Epygenix Tx
What companies will be next? 🤔
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Harmony Biosciences(HRMY.US$ acquired Epygenix Tx
What companies will be next? 🤔
7
$Biogen(BIIB.US$ 📣 Acquires Human Immunology Biosciences (HI-Bio)
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
4
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
7
Read more